#1 Clinical Trials Search in Europe

Clemizole Hydrochloride

Clemizole Hydrochloride, also known as EPX-100, is a drug currently being studied in clinical trials for its potential benefits in treating various medical conditions. These trials aim to evaluate the safety, efficacy, and pharmacokinetics of Clemizole Hydrochloride in patients with hepatocellular carcinoma, hepatitis C, Dravet syndrome, and Lennox-Gastaut syndrome. The research involves different dosages and administration methods to determine the optimal use of this drug for each condition.

Table of Contents

What is Clemizole Hydrochloride?

Clemizole Hydrochloride, also known as EPX-100 or simply Clemizole, is a drug that is being studied for its potential to treat various medical conditions. It’s currently undergoing clinical trials to evaluate its effectiveness and safety for different diseases.[1][2][3][4][5]

Clemizole for Hepatocellular Carcinoma

Hepatocellular carcinoma is a type of liver cancer. Researchers are studying Clemizole Hydrochloride as a potential treatment for patients with this condition who are either waiting for a liver transplant or have a tumor that can’t be surgically removed.[1]

The study is testing different doses of Clemizole (200 mg, 300 mg, 400 mg, and 500 mg) given by mouth three times a day for up to six months. The main goals are to:

  • Check if the drug is safe and well-tolerated
  • See if it helps shrink or stop the growth of tumors
  • Understand how the drug moves through the body (pharmacokinetics)

Researchers will also look at how long any positive effects last and if the treatment helps patients live longer.[1]

Clemizole for Hepatitis C

Hepatitis C is a viral infection that attacks the liver. A study is looking at using Clemizole Hydrochloride in patients with hepatitis C who haven’t been treated before.[2]

In this study, patients take 100 mg of Clemizole twice a day for 28 days. After this, they start the standard hepatitis C treatment (interferon and ribavirin). The study aims to:

  • See how the drug affects the amount of hepatitis C virus in the body
  • Understand how the drug moves through the body
  • Check if the drug is safe and well-tolerated

This research could help determine if Clemizole might be useful as part of hepatitis C treatment.[2]

Clemizole for Dravet Syndrome

Dravet syndrome is a rare, severe form of epilepsy that begins in infancy. Researchers are studying Clemizole (called EPX-100 in this context) as an additional treatment for people with Dravet syndrome.[3]

The study is comparing EPX-100 to a placebo (a substance with no active drug) to see if it can:

  • Reduce the number of seizures
  • Increase the number of days without seizures
  • Improve overall quality of life
  • Reduce the severity of seizures

This research could potentially lead to a new treatment option for people with Dravet syndrome.[3]

Clemizole for Lennox-Gastaut Syndrome

Lennox-Gastaut syndrome (LGS) is another severe form of epilepsy that usually begins in childhood. A study is testing EPX-100 (Clemizole Hydrochloride) as an additional treatment for children with LGS.[5]

The main goal of this study is to see if EPX-100 can reduce the frequency of seizures that cause sudden falls (drop seizures) in children with LGS. The study lasts for 20 weeks, including:

  • 4 weeks of observation before starting the treatment
  • 4 weeks of gradually increasing the dose
  • 12 weeks of maintaining the full dose

After this, participants have the option to continue taking EPX-100 for another 52 weeks in an open-label extension phase.[5]

Safety and Dosage Information

Researchers are carefully studying the safety of Clemizole Hydrochloride. In one study with healthy volunteers, they tested different doses (20 mg, 40 mg, and 80 mg) given twice daily. They looked at:

  • Side effects that occurred during treatment
  • Changes in heart rhythm (measured by ECG)
  • Physical exam findings and body weight changes

They also studied how the drug moves through the body when taken on an empty stomach and after a high-fat meal.[4]

It’s important to note that Clemizole Hydrochloride is still being researched and is not yet approved for general use. The appropriate dosage and safety profile are still being determined through these clinical trials. Always consult with a healthcare professional about any medical treatments or participation in clinical trials.

Aspect Details
Drug Name Clemizole Hydrochloride (EPX-100)
Conditions Studied Hepatocellular Carcinoma, Hepatitis C, Dravet Syndrome, Lennox-Gastaut Syndrome
Administration Oral, various dosages (100-500 mg), 2-3 times daily
Trial Phases Phase 1, Phase 1b, Phase 2a
Primary Outcomes Safety, tolerability, efficacy (disease-specific measures)
Secondary Outcomes Pharmacokinetics, quality of life, long-term effects
Trial Durations 28 days to 24 weeks, with some long-term extensions
Special Assessments Tumor response, viral load, seizure frequency, adverse events

FAQ

  • What medical conditions are being studied with Clemizole Hydrochloride? Clemizole Hydrochloride is being studied for its potential use in treating hepatocellular carcinoma (liver cancer), hepatitis C, Dravet syndrome, and Lennox-Gastaut syndrome.
  • How is Clemizole Hydrochloride administered in these trials? In the trials, Clemizole Hydrochloride is typically administered orally, with dosages ranging from 100 mg to 500 mg, given two to three times daily. The exact dosage and frequency depend on the specific trial and condition being studied.
  • What are the main goals of these clinical trials? The main goals of these trials are to evaluate the safety, tolerability, and efficacy of Clemizole Hydrochloride. They also aim to determine the optimal dosage, assess its pharmacokinetics (how the drug moves through the body), and measure its effects on symptoms and disease progression.
  • How long do these clinical trials typically last? The duration of the trials varies depending on the study design. Some trials last for 28 days, while others can extend up to 24 weeks or even include long-term extension phases of up to 3 years.
  • What are some of the outcomes being measured in these trials? The trials measure various outcomes, including changes in seizure frequency for epilepsy-related conditions, tumor response for cancer studies, viral load for hepatitis C, and overall safety and tolerability. Some studies also assess quality of life improvements and changes in disease-specific symptoms.

Ongoing Clinical Trials on Clemizole Hydrochloride

  • A study to evaluate the effectiveness and safety of clemizole hydrochloride as an additional treatment for patients with Lennox-Gastaut syndrome

    Recruiting

    3 1
    Investigated drugs:
    Czechia Hungary Italy Poland Romania Spain

  • Study on Clemizole Hydrochloride for Children and Adults with Dravet Syndrome

    Recruiting

    3 1
    Investigated drugs:
    Hungary Poland Spain

Glossary

  • Hepatocellular Carcinoma: A type of liver cancer that begins in the main type of liver cell (hepatocyte). It is one of the most common types of cancer worldwide.
  • Dravet Syndrome: A rare, severe form of epilepsy that begins in infancy and is characterized by frequent, prolonged seizures and developmental delays.
  • Lennox-Gastaut Syndrome (LGS): A severe form of epilepsy that typically begins in childhood and is characterized by multiple types of seizures and intellectual disability.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and relationship between drug concentration and effect.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to assess how well a cancer patient responds to treatment.
  • AUC: Area Under the Curve, a measure used in pharmacokinetics to represent the total exposure to a drug over time.
  • Cmax: The maximum (peak) serum concentration that a drug achieves in the body after dosing.
  • Adjunctive Therapy: Additional treatment used together with the primary treatment to increase its effectiveness.
  • Open-Label Extension (OLE): A phase of a clinical trial where all participants receive the active drug, often following the completion of the main study.

References